- Optiscan Imaging (OIL) joins forces with a strategic distribution partner in China
- The company penned a new distributor partnership with Sinsi Technology for the ViewnVivo device which allows real-time in vivo imaging of living tissue
- The new partnership will focus on the greater China market, including Hong Kong and Macau
- Optiscan’s CEO and Managing Director Professor Camile Farah says the new agreement further enhances the reach of the company’s innovative technology into an important and significant segment of the global scientific research market
- Optiscan Imaging is steady on the market, trading at 10 cents at 2:08 pm AEST
Optiscan Imaging (OIL) has joined forces with a strategic distribution partner in China.
The company penned a new distributor partnership with Sinsi Technology for the ViewnVivo device.
ViewnVivo is a miniaturised fluorescence endomicroscope platform that allows real-time in vivo imaging of living tissue.
The new partnership will focus on the greater China market, including Hong Kong and Macau, but exclude the greater Shanghai area and Taiwan due to Optiscan’s existing relationships with local distributors.
Optiscan’s CEO and Managing Director Professor Camile Farah said the new agreement further enhances the reach of the company’s innovative technology into a significant segment of the global scientific research market.
“China represents an excellent growth opportunity for Optiscan’s ViewnVivo product across a range of research and pre-clinical application areas,” she said.
“This is very exciting for Optiscan and for the many research institutes across the broader Chinese market, that now have access to our innovative and cutting-edge technology platform.”
Yan Wang, General Manager of Sinsi Technology, said the technology will undoubtedly increase access to pre-clinical imaging modalities for China-based scientists and medical researchers.
“After more than 20 years of development, Sinsi has accumulated an extensive customer base in life sciences in Greater China, and is looking forward to assisting Optiscan to grow its market share while helping more scientists in China benefit from Optiscan’s ViewnVivo imaging platform,” he said.
Optiscan Imaging was steady on the market, trading at 9.6 cents at 2:08 pm AEST.